Drug Guidance

Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions

Pembrolizumab for treating high-risk early-stage triple-negative breast cancer

Belzutifan for von Hippel-Lindau disease with associated non-metastatic renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumours

Acalabrutinib in combination with bendamustine and rituximab for previously untreated mantle cell lymphoma

Biologics as add-on therapy for treating chronic rhinosinusitis with nasal polyps

Cabozantinib for previously treated well-differentiated pancreatic or extra-pancreatic neuroendocrine tumours

Disease-modifying therapies for treating multiple sclerosis

Durvalumab for limited-stage small-cell lung cancer

Elacestrant for ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation

Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer

-